Palisade Bio opened lower at $1.16, compared with its previous close of $1.17. In the last trading session, the stock traded between $1.13 and $1.18. It showed a downward intraday trend.
An investment of $100 made 5 years ago in Palisade Bio is now worth
$ 0.06
Resulting in a loss of
$ 99.94 (99.94%)
Note: Past profits do not guarantee future returns.
Rating from 4 Analysts
Today's Change
$-0.02 (-2.05%)
Day High
$1.18
Day Low
$1.13
Day Open
$1.16
Prev Close
$1.17
Volume
8,21,055
1W Return
-9.05%
1M Return
-27.56%
3M Return
-46.45%
6M Return
-40.93%
1Y Return
-37.03%
Market Cap ($ Mn)
205
PE Ratio
3.35
PB Ratio
2.87
PEG Ratio
-
ROE
-56.68%
ROCE
-56.29%
EPS (TTM)
$-0.06
1 Week
-9.05%
1 Month
-27.56%
3 Months
-46.45%
6 Months
-40.93%
9 Months
-34.14%
Palisade Bio Q3FY26 Results: Loss per share widens; analysts cut targets
Palisade Bio reported a Q3FY26 net loss of $14.6 million, with loss per share at $0.07. Loss per share missed consensus estimate of $(0.06) by 16.67%. R&D expenses rose to $10.6 million from $1.4 million YoY due to trial activities. HC Wainwright and Piper Sandler analysts lowered price targets to $5 and $16 respectively.
YesterdayPalisade Bio presents PALI-2108 Phase 1b findings at UEG Week 2026
PALI-2108 demonstrated 47.5% reduction in mean endoscopic disease activity in fibrostenotic Crohn’s disease. Mean fecal calprotectin decreased by 58.8% after 14 days of treatment in the Phase 1b cohort. Intestinal tissue concentrations of active metabolite were 7.3-fold higher than peak plasma concentrations. All five patients in the ulcerative colitis cohort achieved clinical response at Day 7. Phase 2b ASCENTRA-UC study enrolling approximately 204 patients supports future efficacy evaluation.
23 days agoPalisade Bio presents five PALI-2108 findings at ACG 2026
Palisade Bio presented five abstracts on PALI-2108 at ACG 2026. Two presentations selected for ACG Presidential Poster Awards. Data supports Phase 2 development for ulcerative colitis and Crohn's disease. Microbiome analyses support potential precision medicine approach.
1mo agoPalisade Bio secures Health Canada clearance for ASCENTRA-UC trial
Health Canada cleared the Clinical Trial Application for Palisade Bio's ASCENTRA-UC study. The global Phase 2 trial evaluates PALI-2108 for moderately to severely active ulcerative colitis. Clearance enables trial activities in Canada, expanding geographic reach beyond the US. Primary efficacy results from the 12-week induction period are expected in H2 2027.
1mo agoPalisade Bio to present at Stifel Immunology forum on September 23
Palisade Bio to present at Stifel 2026 Virtual Immunology and Inflammation Forum. Session scheduled for September 23, 2026, from 1:00 pm to 1:25 pm ET. CEO JD Finley and CMO Mitchell Jones will lead the virtual presentation. Update to cover PALI-2108 progress in ulcerative colitis and Crohn's disease. Live webcast available on company website with limited-time replay access.
1mo agoPalisade Bio Q2 loss widens to $10.6M as R&D costs surge for lead candidate
Palisade Bio's Q2 net loss widened to $10.6M as R&D expenses surged to $7.4M for its lead candidate PALI-2108. Despite the loss, EPS of $(0.05) met analyst expectations, and the company holds $125.2M in cash to fund Phase 2 trials.
3mo ago| Stock | LTP | Change % | Market Cap | PE |
|---|---|---|---|---|
| $547.03 | -0.16% | $1,38,692.89M | 31.55 | |
| $61.05 | +0.38% | $1,31,510.31M | 14.39 | |
| $248.69 | -0.85% | $1,00,625.20M | - | |
| $959.41 | +4.73% | $97,505.80M | 19.64 | |
| $977.58 | +0.62% | $61,476.10M | 38.99 | |
| $419.98 | -0.95% | $46,108.31M | 65.60 | |
| $180.70 | -6.40% | $39,083.96M | - | |
| $53.87 | -0.37% | $33,618.11M | 26.24 | |
| $70.01 | +0.81% | $31,173.07M | 32.37 | |
| $41.85 | +1.60% | $30,322.88M | - | |
| $120.75 | +1.05% | $26,490.14M | - | |
| $122.27 | +1.64% | $24,922.54M | 15.85 |
An investment of $100 made 5 years ago in Palisade Bio is now worth
$ 0.06
Resulting in a loss of
$ 99.94 (99.94%)
Note: Past profits do not guarantee future returns.
